Pizzonero et al. [23] demonstrated that the FFAR2 antagonist GLPG 0974 contributes to inhibition of acetate-induced neutrophil migration and is responsible for reduction of a neutrophil-based pharmacodynamics marker and CD11b activation-specific epitope in a human whole blood assay, suggesting that FFAR2 could be a potential pharmacological target for anti-IBD drugs. The gene discussed is FFAR2; the disease is inflammatory bowel disease.